Clinical trials: Oral Cavity Carcinoma
Oral Squamous Cell Carcinoma
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with…
- Trial name
- NCT05893888
- Testing
- PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable)
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Privo Technologies
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation.
- Conditions
- HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- HPV (NCT05608369)
- Testing
- Cisplatin, Radiation therapy, Vorinostat
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Oropharynx Cancer, Hypopharynx Cancer
Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer
The purpose of this study is to evaluate the benefit of a mouthwash with a phytopharmaceutical preparation, Homeodent®, compared to a mouthwash solution containing sodium bicarbonate, for prevention of severe mucositis (grade ≥3…
- Trial name
- NCT01066741
- Testing
- Homeodent®, 1.4% Sodium Bicarbonate solution
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Centre Leon Berard
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer…
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT01810913
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 342 sites in United States, Canada and 1 more
- Volunteers
- 613 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
The purpose of this study is to assess the safety and tolerability of ASP8273 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
- Trial name
- NCT02113813
- Testing
- naquotinib, midazolam
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck.
- Conditions
- Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT00084682
- Testing
- romidepsin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Oral Squamous Cell Carcinoma
Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma
Controversy over surgical treatment of clinically negative neck in early stage oral squamous cell carcinoma revolves around the uncertainty of its impact on patient prognosis.
- Trial name
- NCT01334320
- Testing
- elective neck dissection
- Where
- 4 sites in China
- Volunteers
- 448 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Vulvar Cancer
CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas
The current project is based on the assumption that a diagnosis of human papillomavirus associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx…
- Conditions
- Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer
- Trial name
- CaptHPV (NCT02981862)
- Testing
- CaptHPV method
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut de Cancérologie de Lorraine
Non-small Cell Lung Cancer
An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Purpose of the study is to determine the following in patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. the safety and tolerability of ASP8273. the pharmacokinetics (PK) of ASP8273.
- Trial name
- NCT02192697
- Testing
- ASP8273
- Where
- 14 sites in Japan, South Korea and 1 more
- Volunteers
- 124 people
- Sponsor
- Astellas Pharma Inc
Head and Neck Cancer, Carcinoma, Squamous Cell
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
- Trial name
- INFIELD (NCT03067610)
- Testing
- Intensity Modulated Radiation Therapy, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma, Non-Small-Cell Lung
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Part A: To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of Xentuzumab (BI 836845) in combination with afatinib in patients with non-small cell lung cancer with progression following prior…
- Trial name
- NCT02191891
- Testing
- Xentuzumab, Afatinib
- Where
- 10 sites in Japan, Singapore and 2 more
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
The goal of this clinical research study is to learn if utomilumab, when given with ISA101b, is able to shrink or slow the growth of tumors in patients with incurable HPV+ oropharyngeal squamous cell carcinoma.
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Trial name
- NCT03258008
- Testing
- Utomilumab, ISA101b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Hepatocellular
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy
- Trial name
- NCT01594125
- Testing
- Nintedanib high dose, Nintedanib low dose, Nintedanib medium dose
- Where
- 5 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Undifferentiated Carcinoma
Cyclophosphamide for Nasopharyngeal Carcinoma
There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02794077
- Testing
- Cyclophosphamide
- Volunteers
- 56 people
- Sponsor
- The University of Hong Kong
Colorectal Cancer, Metastatic Cancer
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery…
- Trial name
- NCT00005030
- Testing
- SCH 66336, conventional surgery
- Sponsor
- M.D. Anderson Cancer Center
Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor…
- Trial name
- NCT06686602
- Testing
- No drug
- Where
- United States
- Volunteers
- 13,759 people
- Sponsor
- Daiichi Sankyo
Head and Neck Cancer
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002702
- Testing
- aldesleukin, adjuvant therapy, conventional surgery
- Where
- 7 sites in Italy
- Volunteers
- 260 people
- Sponsor
- European Institute of Oncology
Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
This study is a superiority multi-center, open-label, phase III randomized controlled trial. It will further verify the clinical value of xidili single-antibody combined with chemotherapy (albumin paclitaxel and carboplatin) in…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
- Trial name
- NCT07827872
- Testing
- Sintilimab, Nab-Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- caohaotian
Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder
NBI for Early Diagnosis of OPMD/OSCC
Early detection - possibly at its pre-malignant stages (Oral Potentially Malignant Disorders, OPMD) - with periodic surveillance is thus fundamental for limiting disease burden, hopefully reducing the incidence of advanced stages…
- Trial name
- NBI_Oral (NCT06438939)
- Testing
- Biopsy for diagnostical purposes
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Cardarelli Hospital
Bladder Cancer, Cervical Cancer
Zinc Supplements in Lowering Cadmium Levels in Smokers
RATIONALE: Zinc supplements may lower cadmium levels in smokers and may help prevent DNA damage. PURPOSE: This clinical trial is studying how well zinc supplements work in lowering cadmium levels in smokers.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00376987
- Testing
- zinc oxide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.